Transgenomic's Q4 Revenues Slide 22 Percent
March 11, 2011
Transgenomic's Q4 Revenues Slide 22 Percent
Transgenomic's CEO said that its acquisition of Clinical Data's testing and biomarker development business in December will give the firm an additional $13 million in revenue annually while providing it "a much larger presence both with insurers and patients."
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Transgenomic's Q4 Revenues Slip 15 Percent on Weaker Diagnostic Tools Sales
March 13, 2013 / GenomeWeb Daily News - Transgenomic's Q4 Revenues Increase 69 Percent
March 7, 2012 / GenomeWeb Daily News - Transgenomic's Q1 Revenues Increase 8 Percent
May 7, 2010 / GenomeWeb Daily News - People in the News: Transgenomic CCO Resigns; Costa Joins Illumina
May 9, 2013 / PCR Insider - Transgenomic's Q1 Revenues Increase 2 Percent
May 8, 2013 / GenomeWeb Daily News